➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Harvard Business School
Colorcon
Mallinckrodt
Baxter

Last Updated: October 22, 2020

DrugPatentWatch Database Preview

Patent: 9,775,915

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,775,915
Title:Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof
Abstract: Provided herein are trioxacarcin-antibody drug conjugates of Formula (A): and pharmaceutically acceptable salts thereof, comprising at least one instance of the group -L.sup.1-(A-L.sup.2)a-B attached thereto, wherein a is an integer between 1 and 10, inclusive, L.sup.1 is absent or is a linking group, A is a moiety formed from the reaction of two complimentary groups (X and Y), L.sup.2 is absent or is another linking group, and B is an antibody or antibody fragment. Also provided are methods of preparing these antibody-drug conjugates, pharmaceutically acceptable compositions thereof, and methods of their use and treatment. Further provided are precursors to the trioxacarcin-antibody drug conjugates, novel trioxacarcins without an antibody conjugated thereto, pharmaceutical compositions thereof, and methods of their use and treatment. ##STR00001##
Inventor(s): Myers; Andrew G. (Boston, MA), Smaltz; Daniel J. (Cambridge, MA), Schumacher; Andreas (Bottmingen, CH)
Assignee: President and Fellows of Harvard College (Cambridge, MA)
Application Number:14/647,198
Patent Claims:see list of patent claims

Details for Patent 9,775,915

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial President and Fellows of Harvard College (Cambridge, MA) 2032-11-26 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial President and Fellows of Harvard College (Cambridge, MA) 2032-11-26 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial President and Fellows of Harvard College (Cambridge, MA) 2032-11-26 RX Orphan search
Glaxosmithkline Llc BENLYSTA belimumab INJECTABLE;INJECTION 761043 001 2017-07-20   Start Trial President and Fellows of Harvard College (Cambridge, MA) 2032-11-26 RX search
Eli Lilly And Co LARTRUVO olaratumab INJECTABLE; INJECTION 761038 001 2019-07-10   Start Trial President and Fellows of Harvard College (Cambridge, MA) 2032-11-26 RX Orphan search
Bristol Myers Squibb EMPLICITI elotuzumab INJECTABLE;INJECTION 761035 002 2015-11-30   Start Trial President and Fellows of Harvard College (Cambridge, MA) 2032-11-26 RX Orphan search
Bristol Myers Squibb EMPLICITI elotuzumab INJECTABLE;INJECTION 761035 001 2015-11-30   Start Trial President and Fellows of Harvard College (Cambridge, MA) 2032-11-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Express Scripts
Merck
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.